UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2020
Commission File Number: 001-39487
Silence Therapeutics plc
(Exact Name of Registrant as Specified in Its Charter)
72 Hammersmith Road
London W14 8TH
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On November 16, 2020, Silence Therapeutics plc (the Company) issued a press release announcing that the Company presented positive pre-clinical safety data for its wholly owned lead product candidate, SLN360, at the American Heart Association’s virtual Scientific Sessions 2020, being held 14-16 November.
A copy of the press release is furnished as Exhibit 99.1 to this Report on Form 6-K.
EXHIBIT INDEX
Exhibit |
| Description |
|
|
|
99.1 |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Silence Therapeutics plc | ||
|
|
| |
| By: | /s/ Mark Rothera | |
|
|
|
|
|
| Name: | Mark Rothera |
|
| Title: | President and Chief Executive Officer |
Date: November 16, 2020